News Archive

Rare Disease Day 2020

Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives

ASH FAQs re: COVID-19 and Thrombotic Thrombocytopenic Purpura

The American Society of Hematology (ASH) has posted FAQs regarding new considerations for TTP treatment during the COVID -19 pandemic. This information is available on their website. Input from Drs. Spero Cataland, Paul Coppo, Marie Scully, Masanori Matsumoto, James George, Bernhard Lämmle, Flora Peyvandi, and Ravi Sarode.

Medscape Releases a CME Accredited Activity About TTP

Medscape, a well known global online platform for the medical community, has added a new CME (Continuing Medical Education) accredited activity to increase knowledge about the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP) entitled "Advances in iTTP: How Can New Therapeutic Options Improve Patient Care?" .

2020 Research Proposal Deadline EXTENDED

Due to the COVID-19 pandemic, the 2020 Answering TTP research grant competition deadline has been extended at least two months, until June 1, 2020. As the situation continues to evolve we will consider further extensions. Take care.

Caplacizumab is Approved by Health Canada

March 2, 2020: Caplacizumab has been approved by Health Canada for the treatment of adults with aTTP in combination with plasma echange and immunosuppressive therapy. Answering TTP Foundation is looking forward to working with provincial and territorial partners to ensure that this therapy is quickly made available at TTP treatment centers across the country and receives timely reimbursement by public and private plans.
Support Groups

Update on Pilot Program -- Virtual Peer Support Pilot Videoconference

The first Virtual Peer Support session was held on Jan 16, 2020 and was a success! We had a total of eight participants from Canada and the U.S.A., which made for some meaningful time to learn and share from each other. Participants included those diagnosed with TTP (both recently and dating back years) and family members.

Our next session will be help on May 14, 2020. Again, call in details will be circulated about a week prior to the date via Community Annoucement to the Answering TTP Community.

Industry aTTP Patient Focus Group Opportunity

A healthcare research firm is recruiting patients from accross Canada to share their experiences with aTTP. The purpose of this focus group will be to help a particular pharmaceutical company understand the aTTP journey and the types of support from which aTTP patients can benefit. Participation should take 2 hours, and compensation will be provided for participant's time.